Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Thenorth1990on Jul 02, 2021 6:42pm
217 Views
Post# 33488611

Management

ManagementThe guys on top are there for a reason, there is no point bashing them every now and then. For me personally their success was getting the guys from Boston before the biogen Judegment day and the gamble to align ourselves with aducanumab kind of paid off. I do hate the fact that they don't stick to the timeliness they provide and thankfully they have the forward looking statement disclosure to hide behind. -Waiting for an update on Serology , probably the most disappointing work yet by promis. We were all told that this would be ready by last summer and expected revenues q4 2020. I hope we had some way of keeping them accountable. We all know this has potential and now it's been validated. When this happens it will be huge for sure, but my hopes for some sp action happening this quarter is dead. Happy Weekend
<< Previous
Bullboard Posts
Next >>